Sign in to view content

Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Jennifer I. Lim, MD, FARVO, FASRS

Video
Published 2022

Related

Benefits and Value of Treatment for Diabetic Macular Edema
Paul Hahn, MD, PhD, FASRS
Updates from the Field
2022
Episode 15: Serum VEGF Levels in the IVAN Trial with Dr. Usha Chakravarthy
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019

Category: Diabetic Retinopathy

See more